Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABL103 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABL103 (DL1) + pembrolizumab | EXPERIMENTAL | Safety Lead-in Part 1 |
| ABL103 (DL2-1) + pembrolizumab + taxane | EXPERIMENTAL | Safety Lead-in Part 2 |
| ABL103 (DL2) + pembrolizumab + taxane | EXPERIMENTAL | Safety Lead-in Part 2 |
| Group 1) ABL103 + pembrolizumab + taxane | EXPERIMENTAL | Dose-expansion Part |
| Group 2) ABL103 + pembrolizumab + taxane | EXPERIMENTAL | Dose-expansion Part |
| Name | Type | Description |
|---|---|---|
| ABL103 | DRUG | IV infusion |
| KEYTRUDA® (pembrolizumab) | DRUG | IV infusion |
| Taxane | DRUG | IV infusion |
Inclusion Criteria: * Subject must understand and be willing to provide informed consent and be able to comply with the study procedures and restrictions. * Subjects must be ≥18 years of age on the day of signing the informed consent form (ICF). * Subject must have a histologically or cytologically...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ABL103 is an investigational small molecule being studied for the treatment of advanced or metastatic solid tumors. It is currently in Phase 1 clinical development, evaluated in combination with pembrolizumab, with or without a taxane, in patients with solid tumors.
ABL103 is being developed by Merck & Company, Inc., traded on the New York Stock Exchange under the ticker MRK. The company is conducting a Phase 1 clinical trial of ABL103 in advanced or metastatic solid tumors.
ABL103 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being studied in a recruiting Phase 1 trial for advanced or metastatic solid tumors.
ABL103 is being studied in one active clinical trial, NCT07158918, titled 'ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors.' This Phase 1 trial is recruiting 65 participants in the United States, Australia, and South Korea.
Yes, the Phase 1 trial of ABL103 (NCT07158918) is randomized and controlled, but it is not double-blinded. The trial is biomarker-selected and enrolls patients aged 18 years and older with solid tumors.